Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:1971
|
| gptkbp:atccode |
J01 AA08
|
| gptkbp:available_on |
gptkb:tablet
gptkb:capsule suspension injection |
| gptkbp:brand |
Minocin
Solodyn |
| gptkbp:casnumber |
10118-79-5
|
| gptkbp:chemical_formula |
C23 H27 N3 O7 S
|
| gptkbp:class |
tetracycline antibiotic
|
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:contraindication |
gptkb:disease
liver disease pregnancy allergy to tetracyclines children under 8 years |
| gptkbp:developed_by |
Lederle Laboratories
|
| gptkbp:dosage_form |
100 mg
50 mg 200 mg 150 mg |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral suspension
extended-release topical gel immediate-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Minocycline
|
| gptkbp:interacts_with |
gptkb:methotrexate
antacids anticoagulants oral contraceptives |
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:lifespan |
16 hours
|
| gptkbp:mechanism_of_action |
inhibits protein synthesis
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
gptkb:Skin
gptkb:rheumatoid_arthritis gptkb:neurodegenerative_diseases cancer therapy chronic obstructive pulmonary disease |
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
dizziness
nausea liver toxicity skin rash photosensitivity pseudomembranous colitis esophageal irritation tooth discoloration |
| gptkbp:used_for |
periodontal disease
bacterial infections acne |
| gptkbp:bfsParent |
gptkb:Arestin
|
| gptkbp:bfsLayer |
7
|